Position Statement on Topical Calcineurin Inhibitors April 2005 On February 15, 2005 the US Food and Drug Administration (FDA) Pediatric Advisory Committee met to discuss the risk evaluation, labeling, risk communication - Hypersensitivity - Document - PDFSEARCH.IO

First Page	Meta Content
	Position Statement on Topical Calcineurin Inhibitors April 2005 On February 15, 2005 the US Food and Drug Administration (FDA) Pediatric Advisory Committee met to discuss the risk evaluation, labeling, risk communication Add to Reading List Document Date: 2012-06-07 06:05:44 Open Document File Size: 164,28 KB Share Result on Facebook Company Fujisawa / Novartis / / Country Canada / / IndustryTerm products / / MedicalCondition metastatic angiosarcoma / squamous cell carcinoma / cancer / atopic dermatitis / lymphoma / tumors / colonic carcinoma / lymphoma development / hepatoblastoma / hypersensitivity / systemic infections / observed lymphomas / Sezary syndrome / lymphomas / nonmelanoma skin cancers / / MedicalTreatment immunization / immunosuppression / / Organization Therapeutic Product Directorate / Pediatric Advisory Committee / US Food and Drug Administration / Canadian Dermatology Association / / SocialTag Pimecrolimus Medicine Tacrolimus Lymphoma Atopic dermatitis Calcineurin Atopy Melanoma Hand eczema Immunosuppressants

Position Statement on Topical Calcineurin Inhibitors April 2005 On February 15, 2005 the US Food and Drug Administration (FDA) Pediatric Advisory Committee met to discuss the risk evaluation, labeling, risk communicationAdd to Reading List